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Abstract
Background: Currently, there are no available targeted therapy options for non-V600 BRAF mutated tumors. The
aim of this study was to investigate the effects of RAF and MEK concurrent inhibition on tumor growth, migration,
signaling and apoptosis induction in preclinical models of non-V600 BRAF mutant tumor cell lines.
Methods: Six BRAF mutated human tumor cell lines CRL5885 (G466 V), WM3629 (D594G), WM3670 (G469E),
MDAMB231 (G464 V), CRL5922 (L597 V) and A375 (V600E as control) were investigated. Pan-RAF inhibitor
(sorafenib or AZ628) and MEK inhibitor (selumetinib) or their combination were used in in vitro viability, video
microscopy, immunoblot, cell cycle and TUNEL assays. The in vivo effects of the drugs were assessed in an
orthotopic NSG mouse breast cancer model.
Results: All cell lines showed a significant growth inhibition with synergism in the sorafenib/AZ628 and selumetinib
combination. Combination treatment resulted in higher Erk1/2 inhibition and in increased induction of apoptosis when
compared to single agent treatments. However, single selumetinib treatment could cause adverse therapeutic effects,
like increased cell migration in certain cells, selumetinib and sorafenib combination treatment lowered migratory
capacity in all the cell lines. Importantly, combination resulted in significantly increased tumor growth inhibition
in orthotropic xenografts of MDAMB231 cells when compared to sorafenib - but not to selumetinib – treatment.
Conclusions: Our data suggests that combined blocking of RAF and MEK may achieve increased therapeutic
response in non-V600 BRAF mutant tumors.
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Background
The RAS/RAF/MEK/ERK pathway consists of numerous
signaling elements that, when affected by mutations, can
promote tumorigenesis and tumor progression [1]. One
of the most frequent cause of RAS/RAF/MEK/ERK
pathway aberrant activation is BRAF gain-of function
mutation (7–15%) [2, 3]. More than 80% of BRAF muta-
tions are single amino acid substitutions of valin for
glutamic acid in position 600 (V600E). Additionally,
BRAF V600 K mutations also occur frequently in BRAF-
mutated melanoma (7–19%) [3]. However incidence of
non-V600 BRAF mutation is not negligible in certain
cancer types. Lung adenocarcinoma, melanoma and
colorectal cancer with BRAF mutation showed 50–86,
34 and 23% non-V600 BRAF mutation frequency, re-
spectively [4–6]. Despite the notable number of the
cases, there is no effective targeted therapy against non-
V600 BRAF mutant tumors.
RAS/RAF/MEK/ERK pathway vertical inhibition in
treatment of V600 BRAF mutant melanoma is already
approved in clinical practice. Compared to V600 mutant
BRAF single inhibition, combination inhibition of V600
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mutant BRAF and MEK displayed elevated progression
free and overall survival in clinical trials with metastatic
BRAFV600 mutant melanoma patients [7, 8]. Also re-
cent studies have shown that in NRAS mutant melan-
oma, RAS/RAF/MEK/ERK pathway vertical inhibition
leads to a synergistic inhibitory effect [9, 10]. Pan-RAF
and MEK double treatment proved to be an effective
therapeutic strategy in vitro in NRAS mutant melano-
mas, when RAS/RAF/MEK/ERK pathway is activated
and dependence of proliferation and survival on this
pathway is demonstrable [9]. Furthermore MEK and
ERK1/2 combination inhibition induced a high level of
apoptosis in NRAS mutant melanoma cell lines [10].
Also in KRAS mutant colorectal and lung cancer cell
lines RAF and MEK combination inhibition abrogates
ERK1/2 signaling and triggers apoptosis [11]. Enhanced
therapeutic effects of MEK inhibitor and pan-RAF in-
hibitor (sorafenib) combination therapies have already
been described in hepatocellular, thyroid, lymphoma and
renal carcinoma [12–15].
Non-V600 BRAF mutant tumors often carry concomi-
tant mutations in RAS or PI3K [6]. NRAS or KRAS mu-
tations frequently occur concurrently with kinase dead
BRAF mutations and play a role in MAPK pathway ac-
tivity maintenance via CRAF [6, 16, 17]. Also the MAPK
pathway could be still activated through dimerization of
BRAF with reduced kinase activity and wild-type CRAF
[2, 6, 18]. Since in non-V600 BRAF mutant tumor cells
the MAPK pathway could still play a dominant role via
CRAF in proliferation, survival and migration, we hy-
pothesized that vertical inhibition of RAF and MEK may
lead to enhanced therapeutic effects as found previously
in V600 BRAF mutant cells.
The aim of our study was to investigate the effect of
pan-RAF inhibitors (sorafenib and AZ628) and MEK in-
hibitor (selumetinib) combination treatment on non-
V600 BRAF mutant tumor cell lines with various BRAF
activities (Table 1). Sorafenib has broad preclinical activ-
ity across tumor types. While sorafenib had the lowest
IC50 values against CRAF and wild-type BRAF, 6 and
22 nM, respectively, and thus can be considered a pan-
RAF inhibitor, it also targets a variety of other kinases
including VEGFR-1, VEGFR-2, VEGFR-3, PDGFR, c-Kit,
Flt-3 and RET. [19, 20]. AZ628 has strong selectivity for
RAF kinases with an IC50 value of 30 nM for BRAF
V600E and wild-type CRAF and of 100 nM for wild-type
BRAF [21]. Selumetinib is a non-ATP competitive and
highly selective MEK 1/2 inhibitor. In clinical trials with
selumetinib, patients harboring RAS/RAF mutations had
higher objective response rate than patients with wild-
type RAS/RAF [22].
Here, we report that in preclinical models of non-
V600 BRAF mutant tumors, combination of sorafenib/
AZ628 and selumetinib shows enhanced therapeutic ef-
fects compared to single treatment.
Methods
Reagents and cell lines
Selumetinib, sorafenib and AZ628 were obtained from
Selleck Chemicals (Houston, TX), LC Laboratories (Wo-
burn, MA) and Sigma-Aldrich (St. Louis, MO), respect-
ively. Six human tumor cell lines were used in the
experiments. Cell lines A375 (ATCC, CRL-1619),
CRL5885 (ATCC, CRL-5885), CRL5922 (ATCC, CRL-
5922) and MDAMB231 (ATCC, HTB-26) are available
from ATCC. WM3629 (Coriell Cat# WC00117, RRID:
CVCL_C275), WM3670 (Coriell Cat# WC00119, RRID:
CVCL_6799) cell lines were obtained from the Wistar
Institute (Table 1). Activation status of the BRAF muta-
tions are from Zheng et al., 2015 [6]. Cell lines have no
known additional mutations in PI3K or PTEN [23–27].
All cell lines were cultured in DMEM (Lonza,
Switzerland; with 4500 mg/dm3 glucose, piruvate and L-
glutamine) supplemented with 10% foetal calf serum
(Gibco) and 1% penicillin-streptomycin-amphotericin
(Lonza). Cells were maintained in tissue culture flasks at
37 Co with 5% CO2.
Sulforhodamine B (SRB) assay and drug combinatory
index assessment
Long-term antiproliferative effects of sorafenib and selu-
metinib treatment were assessed by performing clono-
genic SRB (Sigma-Aldrich, St. Louis, MO) assays. Briefly,
2000 cells (WM3629, WM3670, CRL5885, CRL5922) or
250 cells (A375, MDAMB231) were plated in 24-well
plate format and cultured overnight. Next day, the cells
were treated with different concentrations of sorafenib
or AZ628 and selumetinib and with combined treatment
for 10 days. After 10 days, cell monolayers were fixed
with 10% trichloroacetic acid and stained for 15 min
with SRB. Excess stain was discarded and cells were
washed with 1% acetic acid solution. Stained cells were
dissolved in 10 mM Tris-HCl pH 8 and OD was mea-
sured at 570 nm using a microplate reader (EL800, Bio-
Tec Instruments, Winooski, VT). Interactions between
drugs were tested on the basis of calculating the com-
bination index (CI) according to Chou and Talalay [28]
Table 1 Cell lines by tissue type, BRAF and RAS mutational
status
Cell lines Tissue BRAF BRAF activity RAS (N/K) Reference
A375 melanoma V600E high wild type [45]
CRL5885 lung G466 V low wild type [25]
WM3629 melanoma D594G low G12D (N) [27]
WM3670 melanoma G469E low G12D (N) [27]
MDAMB231 breast G464 V intermediate G13D (K) [46]
CRL5922 lung L597 V intermediate Q61K (N) [47]
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with CompuSyn software (ComboSyn Inc). CI values CI
< 1, CI = 1 or CI > 1 represents synergism, additive ef-
fects, and antagonism, respectively.
Immunoblot analysis
Immunoblot analysis was performed to demonstrate the
effect of selumetinib and sorafenib treatment on the ac-
tivation of CRAF, Erk1/2, Akt (at Ser473) and S6 protein.
Induction of apoptosis upon selumetinib and sorafenib/
AZ628 treatment was detected by total PARP and
cleaved PARP. Cells were seeded in six-well plates and
maintained overnight. Next day selumetinib and sorafe-
nib/AZ628 or combination treatment were applied for
4 h or 48 h to determine the activation changes of
CRAF, Erk, Akt and S6 or cleavage of PARP, respectively.
For p-CRAF/CRAF, p-Erk1/2/Erk1/2, p-Akt/Akt, p-S6/
S6 detection ice-cold 6% trichloroacetic acid (TCA) were
used to precipitate cells. Then cells were centrifuged for
15 min at 12000×g at 4 °C. Modified Läemmli-type sam-
ple buffer containing 90 mM Tris-HCl, pH 7.9, 2% SDS,
10% glycerol, 5 mM EDTA, 125 mg/ml urea, 100 mM
dithiothreitol (DTT), 0.02% bromophenol blue was used
to dissolve protein pellets. Protein concentrations were
measured by the modified Lowry method using bovine
serum albumin as standard. To detect total/cleaved
PARP cells were lysed with RIPA Buffer (Thermo Scien-
tific, Waltham, MA) supplemented with 1% Halt Prote-
ase Inhibitor Single-Use Cocktail (Thermo Scientific).
Total protein concentrations were measured with Pierce
BCA Protein Assay kit (Thermo Scientific). Protein sam-
ples were separated by SDS-PAGE (10%) and transferred
to PVDF membranes (Thermo Scientific). Primary anti-
bodies to antiPARP/cleaved-PARP (Merck Millipore
AM30, Cell Signaling; #9541) and anti p-Erk1/2/Erk1/2,
p-Akt/Akt, p-S6/S6, p-CRAF/CRAF (Cell Signaling;
#9101, #9102, #4058, #9272 #2215, #2217, #9427, #9422,
respectively) and as loading control anti β-tubulin or β-
actin (Cell Signaling #2128 and #4970), overnight at 4 °C
in a dilution of 1:1000 were applied. Secondary HRP-
conjugated anti-rabbit or anti-mouse antibody (Jackson
ImmunoResearch, West Grove, PA) was used (1:10000,
1 h) at room temperature. Pierce ECL Western Blotting
Substrate (Thermo Scientific) was used to visualize the
protein bands.
TUNEL assay
Cells were seeded in 24 well plates (50,000 cells/well)
and next day selumetinib or sorafenib or a combined
treatment were applied. After 48 h of treatment 4% buff-
ered formalin was used to fix the cells. Labelling of ter-
minal deoxynucleotidyl transferase—mediated dUTP
nick end (TUNEL) was performed according to the sup-
plier’s recommendation (Roche Diagnostics, Basel,
Switzerland). DAPI stained and TUNEL positive nuclei
on at least three 10× microscopic fields were counted to
quantify the images.
Cell cycle analysis
To determine cell cycle change upon selumetinib and
sorafenib treatment, cells were treated with the inhibi-
tors for 48 h in 6-well plates. Cell cycle analysis was car-
ried out as described earlier [29]. Briefly, cells were
trypsinized and lysed before staining with DAPI for 5
min at 37 °C. After adding the stabilization buffer, sam-
ples was loaded onto an 8-well NC slide. NucleoCounter
NC-3000™ system (Chemometec, Allerod, Denmark) was
used to quantify cellular fluorescence.
Time-lapse video microscopy
Video microscopy measurements were performed and
analyzed as described previously [30]. The parameter
migrated distance is calculated by averaging for each cell
the displacement for the 48–60 h interval after treat-
ment, in at least three independent experiments and
three microscopic fields.
Mammary xenografts of MDAMB231 breast cancer cells
Animal experiments were carried out at the Department
of Experimental Pharmacology, National Institute of
Oncology, Budapest, Hungary and the animal-model
experiments were conducted following the standards
and procedures approved by the Animal Care and Use
Committee of the National Institute of Oncology,
Budapest (license number: PEI/001/2574–6/2015). 14-
weeks-old female NSG mice were used as animal model,
since previous work described NSG mice as a suitable
model for study human breast cancer [31]. Mice were
bred and maintained in specific pathogen-free facility.
MDAMB231 cells (2 × 106 in 50 μl serum-free DMEM)
were injected into the mammary fat pad of female NSG
mice. Two weeks after injection, mice were randomly
and evenly divided into four groups (10 mice/group) and
treated with vehicle, 25 mg/kg sorafenib and 10 mg/kg
selumetinib or both intraperitoneally (i.p) every day ex-
cept weekends for 18 days. Controls received equivalent
amounts of DMSO as treated animals. All animals were
included in the analysis. The changes of the body weight
were also determined throughout the study (Fig. 5b). No
adverse events were observed during the experiment.
Tumors were measured with caliper twice a week and
tumor sizes were calculated with the formula for the vol-
ume of a prolate ellipsoid (length x width2 x (4π/3)) and
then transformed into relative values (V) using the
formula: V = Vt/V0, where V0 is the initial tumor
volume and Vt is the tumor volume at the indicated
time point. Eighteen days after the first treatment, mice
were euthanized and the tumor tissue was removed and
weighed.
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Statistics
All statistical analyses were performed in GraphPad
Prism 5 (GraphPad Software Inc., USA, San Diego, CA).
One-way ANOVA followed by Tukey’s post hoc test was
used to establish whether significant differences existed
between groups. Differences were considered significant
at p < 0.05.
Results
Synergistic effect of sorafenib and selumetinib
combination in non-V600 mutant cell lines
Growth inhibition assays were performed with single
agents or a combination of sorafenib and selumetinib on
a panel of non-V600 mutant human cell lines and
V600E BRAF mutant A375 cell lines (Table 1). Among
these cell lines, the V600E BRAF mutant A375 cell line
was the most sensitive to selumetinib treatment, while
non-V600 BRAF mutant cells showed similar sensitivity
to single selumetinib treatment (Fig. 1a). The growth in-
hibitory effect of sorafenib was also similar among the
cell lines, except the double mutant WM3629, which
was more sensitive compared to the other cells (Fig. 1b).
To identify the synergistic effect of sorafenib and selu-
metinib, dose–response curves were established by via-
bility assays following 10 days selumetinib and sorafenib
combination treatment (Additional file 1: Figure S1).
Combination indices (CI) were calculated by CompuSyn
Software from the data of viability assays of combination
treatment. All cell lines - including the V600E BRAF
mutant A375 at lower selumetinib concentration -
showed lower CI value than 1 indicating synergistic
interaction in combination treatment (Fig. 1c).
Effect of sorafenib and selumetinib combination
treatment on signaling of CRAF, Erk1/2, Akt and S6
kinases
To investigate the effect of selumetinib and sorafenib or
combined treatment on CRAF, Erk1/2, Akt and S6 acti-
vation, cell lines were treated with single agents or the
combination and were analyzed by Western blotting
(Fig. 2). We observed a decrease of Erk1/2 activation in
all non-V600 BRAF mutant cell lines after both sorafe-
nib and selumetinib treatment. In comparison with the
single agent treatment, combination of drugs caused
even further decreases in p-Erk1/2 levels in all cell lines,
except A375, where selumetinib treatment caused
complete Erk1/2 deactivation. Our data suggest that
combination treatment could be more effective for the
blocking of the MAPK pathway in non-V600 BRAF mu-
tant cell lines. In order to measure the effect of sorafenib
and selumetinib on Akt/mTOR pathway, we evaluated
the level of total and phosphorylated Akt and S6 in the
cells. Effect of combination treatment on Akt and S6 ac-
tivation was not uniform in all cell lines. We observed
slightly increased p-Akt levels in WM3629 and
CRL5922, however in the other cell lines Akt activation
decreased or not altered. Also combination of drugs de-
creased or not changed the activation of S6 among the
cell lines. Notably, in WM3629 and WM3670 melanoma
cells single selumetinib treatment also caused increased
activation of Akt. Furthermore, in non-V600 BRAF mu-
tant tumors combination treatment could induce total
CRAF expression but not in V600E BRAF mutant A375.
Also we observed weak induction of CRAF activation
upon sorafenib or selumetinib at Ser338 in CRL5885,
WM3629, WM3670 and MDAMB231.
Sorafenib and selumetinib combination treatment leads
to apoptosis and G0/G1 cell-cycle arrest in non-V600
mutant cell lines
PolyADP-ribose polymerase cleavage (PARP/cleaved
PARP) immunoblot assay (Fig. 3a) and TUNEL staining
(Fig. 3b and c) was used to determine whether growth in-
hibition was due to induction of apoptosis in our panel of
BRAF mutated cell lines. Treatment with selumetinib or
sorafenib alone had either no (WM3670, MDAMB231) or
minimal (A375, CRL5885, CRL5922) effects on cleavage
of PARP, whereas combined treatment resulted in a pro-
nounced increase of PARP degradation (Fig. 3a). The
TUNEL assay data further confirmed this finding. We
observed that combination treatment significantly in-
crease the level of apoptotic cells compared to single treat-
ment. Interestingly, also A375 cell line showed an elevated
apoptotic effect in response to combined treatment. These
results indicate that RAF and MEK1/2 vertical inhibition
increases the potential to trigger apoptosis in non-V600
and also V600E BRAF mutant cells. Also cell cycle
analyses revealed that combination treatment reduced cell
proliferation by arresting cell cycle in G0/G1. Further-
more, we observed elevated subG1 cell population upon
combination treatment in CRL5885 and MDAMB231
cells (Additional file 2: Figure S2).
Migration is inhibited by sorafenib and selumetinib
combination treatment in non-V600 mutant cells
Migratory potential of the cells was evaluated via video
microscopy measurements [30]. Single treatment of selu-
metinib decreased the migratory ability of most non-
V600 BRAF mutant cell lines. Interestingly, in WM3629
melanoma cells selumetinib increased migration. Sorafe-
nib also decreased migration among cell lines. Combin-
ation treatment has no significantly stronger effect on
migration than single agent treatment in neither of cell
lines, however in WM3629 and MDAMB231 we ob-
served statistically significant decrease in migration only
in combination treatment group when compared to
control group (Fig. 4).
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Combination of selumetinib and sorafenib therapy
enhances tumor growth inhibition in MDAMB231
xenograft compared to single agents with negligible
toxicity
We examined the effect of selumetinib, sorafenib or com-
bined treatment on in vivo growth of MDAMB231 cells
transplanted into 14-weeks-old NSG mice. MDAMB231
cells were injected into mammary fat pads of female mice
and animals were monitored for the growth of palpable
tumor at the site of injection. Two weeks after cell injec-
tion, animals received either vehicle as control or selume-
tinib at 10 mg or sorafenib at 25 mg or both (per kg body
weight) daily, except weekends by i.p. injection. We
observed that both sorafenib or selumetinib treatments
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Fig. 1 Growth inhibition assay with single agent or combination of sorafenib and selumetinib. a Cell lines were treated with different concentrations
of selumetinib for ten days (mean values +/− SEM). b Cell lines were treated with different concentrations of sorafenib for ten days (mean values +/−
SEM). c Combination indices (CI) were calculated by CompuSyn Software from the data of viability assays of selumetinib and sorafenib combination
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reduced tumor growth, however the combination resulted
in an enhanced growth inhibitory effect. Tumor growth
inhibition was significantly greater in the combination
group compared to vehicle and sorafenib (Fig. 5a,c and d).
To assess the toxicity associated with the drug treatment,
body weights were monitored throughout the course of
the study. Body weights at day 18 were not significantly
different from day 1 body weight in each group of animals.
Also body weight losses were not significantly different be-
tween treatment groups (Fig. 5b).
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Combination of the selective pan-Raf inhibitor AZ628
and selumetinib also increases growth inhibition and
PARP cleavage activity compared to single treatment in
non-V600 BRAF mutant cells
Since sorafenib also has inhibitory effect on several other
kinases, we performed growth inhibition and PARP
cleavage assay with a highly selective pan-RAF inhibitor
(AZ628) on our panel of non-V600 BRAF mutant cells.
We found that WM3629 and MDAMB231 showed the
highest sensitivity to AZ628 single treatment (Fig. 6a).
Also combination treatment revealed significant syner-
gism between selumetinib (below 0.5 μM concentration)
and AZ628 in all cell models tested (Fig. 6b). Further-
more, the combination of selumetinib with AZ628
enhanced cleavage of PARP in CRL5885, WM3670,
MDAMB231 and CRL5922 and also decreased the total
PARP level in WM3629 cell line (Fig. 6c).
Discussion
Currently there are no approved targeted therapeutic
options for non-V600 BRAF mutant tumors. In our
study we have demonstrated that in non-V600 BRAF
mutant cells the combination of sorafenib and selumeti-
nib treatment synergistically enhances growth inhibition
compared to single treatment. Combination treatment
also improves apoptosis induction and Erk1/2 inhibition
compared to monotherapy and, moreover, also decreases
migratory capacity of the cells. We have also performed
growth inhibition and PARP cleavage assay with highly
selective pan-RAF inhibitor AZ628 to confirm that ef-
fects of sorafenib treatment on non-V600 BRAF mutant
cells are due to its pan-RAF inhibitor activity. We found
that also AZ628 and selumetinib combination treatment
resulted in synergistically increased growth inhibition
and PARP cleavage in non-V600E BRAF mutant cells.
While our study is the first report on sorafenib/AZ628
and selumetinib combination, there are already studies
on non-V600 BRAF mutant lung cancer cell lines using
the BRAF V600E mutant selective inhibitors dabrafenib
or vemurafenib and the MEK inhibitor trametinib [32,
33]. In the H1666 (CRL5885) and H1395 non-V600
BRAF mutant lung cancer cell lines and the H508 colo-
rectal cancer cell line dabrafenib and trametinib combin-
ation treatment showed enhanced anti-proliferative
effects and caspase3/7 activation, however these results
were not significant in all cell lines [33]. In the H1755
non-V600 BRAF mutant lung cancer cell line vemurafe-
nib and trametinib combination treatment caused a
small but significant increase in apoptosis when com-
pared to either single agent [32]. It was also shown that
in low but not in high activity BRAF mutant melanoma
cell lines (WM3670, WM3629) sorafenib treatment
could reduce tumor growth and induce apoptosis [34].
We observed similar effects upon sorafenib treatment in
these cells; however, adding selumetinib further
increased inhibition of tumor growth and migration as
well as enhanced the apoptosis inducing effects of
sorafenib.
Targeted therapy could induce adverse effects on par-
allel signaling pathways. It was previously described that
sorafenib treatment tends to elevate Akt activation in
cell lines with KRAS or BRAF mutations [35]. Also
MEK inhibition could increase p-Akt level in RAF mu-
tant cells [36] and KRAS mutant cells [37]. We observed
that after 4 h treatment of selumetinib p-Akt level in-
creased in WM3670 and WM3629 cells that have low
activity non-V600 BRAF and additional NRAS mutation.
Furthermore, we found that in the WM3629 cell line
selumetinib caused significantly elevated migration
which could be diminished by adding sorafenib. Our
findings suggest that the potentially adverse signaling
effects of selumetinib could be reversed by adding
sorafenib.
We found significant tumor growth inhibition in the
in vivo xenograft model of the MDAMB231 cell line
upon sorafenib and/or selumetinib treatment. Although
the enhanced tumor growth inhibition did not reach
statistical significance between the selumetinib and the
combination treatment group, in the combination group
the variance between relative tumor volumes was signifi-
cantly lower than in the selumetinib group (p = 0.017, F-
test). This observation indicates that combination treat-
ment reduced the number of weak-responders in com-
parison to selumetinib single treatment. Furthermore, a
recent study showed that the selumetinib and sorafenib
combination treatment almost eliminated tumor growth
and reduced metastatic pulmonary tumor burden in in
vivo experiments with MDAMB231 cells [38]. Neverthe-
less, additional in vivo preclinical models need to be in-
vestigated to clarify whether there is a therapeutic
benefit from the combination in non-V600 BRAF mu-
tant tumors.
There is an urgent and unmet need to find effective
therapeutic treatment for non-V600 BRAF mutant tu-
mors. Recent studies show that advanced melanoma and
colorectal cancer patients with non-V600 BRAF muta-
tion have longer overall survival compared those with
both V600E BRAF mutant and wild-type BRAF [39, 40].
However, in non-V600 BRAF mutant melanoma patients
the BRAF V600E selective inhibitors (vemurafenib or
dabrafenib) had only disease progression as the best
response to therapy [39]. Importantly, advanced lung
cancer patients with non-V600 BRAF mutation has
worse overall survival than V600E mutant patients [5,
41, 42]. Of note, it was reported in a case study, that a
female patient with non-V600 BRAF (G469R) mutated
lung adenocarcinoma showed dramatic response to
sorafenib treatment [43].
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Based on our preclinical findings, sorafenib treatment
combined with selumetinib might result in enhanced
therapeutic effect also in patients with non-V600 BRAF
mutant tumors. Since our study investigated only one in
vivo preclinical model, further studies are warranted to
confirm whether combinatorial treatment delivers
additional benefit compared to monotherapy. Regard-
ing the safety of the proposed combination, a recent
phase I study with sorafenib and selumetinib combin-
ation showed promising effectiveness and tolerable
adverse effects in advanced hepatocellular carcinoma
patients [44].
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combination treatment
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Conclusion
Currently, there are no approved targeted therapies for
non-V600 BRAF mutant cancer patients. Our in vitro
data suggests that combination inhibition of RAF and
MEK with sorafenib/AZ628 and selumetinib, respect-
ively, should be further explored as a potential approach
for inhibiting tumor growth in non-V600 BRAF mutant
malignancies.
Additional files
Additional file 1: Figure S1. Dose–response curves for sorafenib
without or with the indicated selumetinib concentrations. Viability was
measured by SRB assay after 10 days drug exposure and normalized to
untreated controls (mean values +/− SEM). The respective combination
indices (CI) were calculated by CompuSyn Software and are shown in
Fig. 1c. (EPS 4764 kb)
Additional file 2: Figure S2. Analysis of cell cycle after treatment with
selumetinib or sorafenib and combination. Cells were treated with
selumetinib (50 nM), sorafenib (1 μM), alone or in combination for 48 h.
C – control, Se – selumetinib, So – sorafenib, Se + So – selumetinib +
sorafenib. (EPS 8097 kb)
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